» Articles » PMID: 24397589

Differential Patterns of Insulin Secretion and Sensitivity in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease Versus Patients with Type 2 Diabetes Mellitus Alone

Overview
Publisher Biomed Central
Date 2014 Jan 9
PMID 24397589
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) often coexist and have adverse outcomes. The aim of our study was to elucidate metabolic abnormalities in patients with DM-NAFLD versus those with T2DM alone.

Methods: Patients were divided into two groups: 26 T2DM patients with NAFLD and 26 gender-, age-, and body mass index-matched patients with T2DM alone. Patients took a 75-g oral glucose tolerance test (OGTT), which measured serum insulin and C-peptide (C-p) levels at baseline (0 min), 30 min, 60 min, and 120 min after glucose challenge.

Results: Patients with DM-NAFLD or T2DM alone had similar blood glucose levels. β-cell hypersecretion was more obvious in patients with DM-NAFLD. In addition, fasting, early-phase, and late-phase C-peptide levels were significantly increased in patients with DM-NAFLD (ΔC-p 0-30 min, P < 0.05; Area Under the Curve (AUC) C-p/PG 30-120 min ratio, P < 0.01; and AUC C-p 30-120 min, P < 0.01). Hepatic and extrahepatic insulin resistance during the OGTT did not differ significantly between groups. Hepatic insulin sensitivity independently contributed to the early phase (0-30 min) of the OGTT in patients with T2DM and NAFLD, whereas a significant deficit in late insulin secretion independently contributed to the 30-120 min glucose status in patients with T2DM only.

Conclusions: In patients with similar levels of insulin resistance and hyperglycemia, DM-NAFLD was associated with higher serum insulin levels than T2DM alone. Hyperinsulinemia is caused mainly by β-cell hypersecretion. The present study demonstrates pathophysiological differences in mechanisms of insulin resistance in patients with DM-NAFLD versus T2DM alone.

Citing Articles

Gamma-Glutamyltransferase Is a Predictor for Future Changes of Diabetogenic Factors in Aged Chinese-A Four-Year Follow-Up Study.

Wong M, Lo C, Chen Y, Chen F, Kuo C, Chen J J Clin Med. 2023; 12(17).

PMID: 37685672 PMC: 10488810. DOI: 10.3390/jcm12175606.


An Atypical Form of Diabetes Among Individuals With Low BMI.

Lontchi-Yimagou E, DasGupta R, Anoop S, Kehlenbrink S, Koppaka S, Goyal A Diabetes Care. 2022; 45(6):1428-1437.

PMID: 35522035 PMC: 9184261. DOI: 10.2337/dc21-1957.


The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.

Kosmalski M, Ziolkowska S, Czarny P, Szemraj J, Pietras T J Clin Med. 2022; 11(5).

PMID: 35268466 PMC: 8910939. DOI: 10.3390/jcm11051375.


Pharmacokinetic and metabolomic analyses of Mangiferin calcium salt in rat models of type 2 diabetes and non-alcoholic fatty liver disease.

Lin H, Teng H, Wu W, Li Y, Lv G, Huang X BMC Pharmacol Toxicol. 2020; 21(1):59.

PMID: 32762728 PMC: 7409647. DOI: 10.1186/s40360-020-00438-x.


Salvianolate Reduces Glucose Metabolism Disorders in Dimethylnitrosamine-Induced Cirrhotic Rats.

Tang L, Tao Y, Liu C, Wang H Chin J Integr Med. 2017; 24(9):661-669.

PMID: 29209957 DOI: 10.1007/s11655-017-2773-5.


References
1.
Smith B, Adams L . Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol. 2011; 7(8):456-65. DOI: 10.1038/nrendo.2011.72. View

2.
Farrell G, Larter C . Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43(2 Suppl 1):S99-S112. DOI: 10.1002/hep.20973. View

3.
Haque M, Sanyal A . The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. 2002; 16(5):709-31. DOI: 10.1053/bega.2002.0325. View

4.
Greco A, Mingrone G, Mari A, Capristo E, Manco M, Gasbarrini G . Mechanisms of hyperinsulinaemia in Child's disease grade B liver cirrhosis investigated in free living conditions. Gut. 2002; 51(6):870-5. PMC: 1773476. DOI: 10.1136/gut.51.6.870. View

5.
Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M . Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001; 50(8):1844-50. DOI: 10.2337/diabetes.50.8.1844. View